Idiopathic Pulmonary Fibrosis: Making Sense of Diagnostic and Therapeutic Options in Primary Care (Jan 23, 2017 - Jan 22, 2018)
WebcastFaculty
OVERVIEW
Idiopathic Pulmonary Fibrosis: Making Sense of Diagnostic and Therapeutic Options in Primary Care is organized by National Association for Continuing Education (NACE) and will be held during Jan 23, 2017 - Jan 22, 2018.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Course Descrption:
This monograph will provide information about Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare, but deadly lung disorder that can be difficult to recognize and diagnose. A type of interstitial lung disease (ILD), IPF is characterized by insidious onset, nonspecific symptoms of cough and dyspnea, and a progressive decline in lung function caused by fibrosis of the lung parenchyma.
The prognosis of IPF is poor. The estimated median survival is 3.8 years from diagnosis, and the only intervention so far shown to improve survival is lung transplantation.1,2 Furthermore, the diagnosis of IPF is often missed or delayed. The gradual onset and nonspecific symptoms of IPF may be inadequately investigated or confused with more common diseases, leaving patients untreated or inappropriately treated. Diagnostic delays may also limit the types of treatments available to patients (such as lung transplantation) and can lead to increased healthcare costs, reduced patient quality of life, and shortened survival.
Conference Objectives are :
• Implement an appropriate strategy for diagnosing a patient with IPF
• Discuss and contrast the available pharmacotherapeutic options for patients with IPF
• Describe the non-pharmacotherapeutic options for IPF patients
• Establish the clear role for the primary care clinician in diagnosing and managing disease in IPF patients
Additional details will be posted as soon as they are available.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Course Descrption:
This monograph will provide information about Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare, but deadly lung disorder that can be difficult to recognize and diagnose. A type of interstitial lung disease (ILD), IPF is characterized by insidious onset, nonspecific symptoms of cough and dyspnea, and a progressive decline in lung function caused by fibrosis of the lung parenchyma.
The prognosis of IPF is poor. The estimated median survival is 3.8 years from diagnosis, and the only intervention so far shown to improve survival is lung transplantation.1,2 Furthermore, the diagnosis of IPF is often missed or delayed. The gradual onset and nonspecific symptoms of IPF may be inadequately investigated or confused with more common diseases, leaving patients untreated or inappropriately treated. Diagnostic delays may also limit the types of treatments available to patients (such as lung transplantation) and can lead to increased healthcare costs, reduced patient quality of life, and shortened survival.
Conference Objectives are :
• Implement an appropriate strategy for diagnosing a patient with IPF
• Discuss and contrast the available pharmacotherapeutic options for patients with IPF
• Describe the non-pharmacotherapeutic options for IPF patients
• Establish the clear role for the primary care clinician in diagnosing and managing disease in IPF patients
Additional details will be posted as soon as they are available.
SPECIALITIES
Pulmonary Medicine
Quick Links